Andecaliximab

Drug Profile

Andecaliximab

Alternative Names: GS 5745; MMP9 mAb inhibitor - Gilead

Latest Information Update: 07 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Gilead Sciences
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Matrix metalloproteinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gastric cancer
  • Phase II/III Ulcerative colitis
  • Phase II Crohn's disease; Cystic fibrosis; Rheumatoid arthritis
  • Phase I Chronic obstructive pulmonary disease; Solid tumours

Most Recent Events

  • 27 Jul 2017 Gilead Sciences terminates a phase II trial in Cystic fibrosis (Adjunctive treatment) in USA, Australia, Canada, Germany, Belgium, France, Ireland, Spain and United Kingdom (SC) (NCT02759562)
  • 14 Jun 2017 Preclinical pharmacodynamics data in Rheumatoid arthritis presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
  • 07 Mar 2017 GS 5745 is now called andecaliximab (NCT01803282)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top